In this review, Tan et al.  provide guidelines that have been developed specifically for the management of MM in Asia. These recommendations take into consideration differing health care resource and expertise across Asian countries.
These guidelines state that IFE and sFLC assessment are essential, especially in patients suspected of having myeloma but who have negative SPE results. Where these tests are not routinely available, physicians are advised to consider sending blood specimens to high-level centres for testing if a diagnosis of LCMM, oligosecretory MM or NSMM is suspected.
In patients with LCMM, oligosecretory MM or NSMM, sFLC analysis should be used for the assessment of response and subsequent progression. Treatment response should be defined according to the IMWG uniform response criteria (Section 25.3.5). The sCR category may be applicable only in centres where sFLC testing is available, and may be more relevant in a clinical trial setting.